Diabetes mellitus will frequently reach a life threatening stage and severely complicate the progress of which can no longer be controlled by insulin alone. It has been known for decades that stem cell therapy is the sole therapy available for such advanced stages of diabetes. There are published data about several thousands of diabetics that have been handled in clinical practice with ever growing success during the last 70 years.
The sooner the patient receives precursor stem cell therapy after the diagnosis of diabetic complication is established, the better will the success rate of the therapy be.
Up to 50% of children with therapeutically uncontrollable ‘brittle’ diabetes had already developed typical diabetic complications by the time of their referral to precursor stem cell therapy. Although majority of such patients have benefited from the mentioned therapy, they could have gained better results by carrying out the implantation at an earlier date.
A number of children with recent onset of diabetes mellitus have been treated successfully with precursor stem cell therapy. Precursor stem cell therapy is able to delay the progression of diabetic complications. If one could postpone the onset of juvenile diabetes by one more year, it would be of tremendous value because of well known deleterious effects of diabetic condition on growth and development of such children.
When a diabetic female patient has been under treatment for infertility for over a year without success, precursor stem cell therapy should be strongly considered. When a pregnant diabetic patient has delivered a baby with a diabetic fetal distress syndrome, precursor stem cell therapy should be carried out before her next pregnancy, or even during her pregnancy (between 12th and 16th week).
The preparation of stem cells by FCTI proprietary method of primary tissue culture, lowers the immunogenicity of stem cell therapy to such a degree that no immunosuppression is required and this is of great importance particularly for the treatment of diabetes mellitus. Besides the known side-effects, the specific problem of immune suppression in diabetics is that it causes an increased metabolic demand on ß–cells from the pancreatic islets so that their capacity to produce insulin may be exhausted. This deleterious effect is much greater for islet cell transplants than for organ transplant of pancreas.
Alexis Carrel, a 2-time Nobel Prize winner in physiology, stated that insulin cannot cure diabetes mellitus, only cell therapy can. This statement is still valid today.
Insulin prevents death of a new diabetic but cannot stop the development of dreaded diabetic complications, severely disabling and frequently deadly after years of suffering.
The cause of all diabetic complications is still unknown but it is probably due to the lack of other ‘still unknown’ hormones produced by various cells of Langerhans islets of the pancreas, or by different cells of various organs of the regulatory system of the carbohydrate and lipid metabolism.
Clinical experience of the past few decades have shown that only precursor stem cell therapy can stop the relentless progress of the complications of diabetes mellitus once they have started.
